Medical technology company Heartflow said on Friday it was targeting a valuation of up to $1.32 billion in its U.S. initial ...

(Reuters) -Cardiac diagnostic software maker Heartflow said on Friday it was targeting a valuation of up to $1.32 billion in ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Lincoln Financial reported strong second-quarter 2025 results that the company said reflects an increasingly diversified earnings mix.

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bain Capital and KKR are among three groups preparing bids for Sapporo Holdings' real estate business, valued at approximately $2.7 billion. Sapporo is selling its real estate hol ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...